[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112021018266A2 - Compositions and methods for treating androgen receptor positive forms of cancer - Google Patents

Compositions and methods for treating androgen receptor positive forms of cancer

Info

Publication number
BR112021018266A2
BR112021018266A2 BR112021018266A BR112021018266A BR112021018266A2 BR 112021018266 A2 BR112021018266 A2 BR 112021018266A2 BR 112021018266 A BR112021018266 A BR 112021018266A BR 112021018266 A BR112021018266 A BR 112021018266A BR 112021018266 A2 BR112021018266 A2 BR 112021018266A2
Authority
BR
Brazil
Prior art keywords
cancer
androgen receptor
compositions
receptor positive
methods
Prior art date
Application number
BR112021018266A
Other languages
Portuguese (pt)
Inventor
Anna Ericsson
Maureen Caligiuri
Qunli Xu
Sylvie Guichard
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/039936 external-priority patent/WO2020006483A1/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of BR112021018266A2 publication Critical patent/BR112021018266A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições e métodos para tratar formas positivas de receptor andrógeno de câncer. a presente invenção refere-se a composições farmacêuticas que compreendem um composto inibidor de cbp que podem ser usadas para tratar pacientes diagnosticados com formas positivas de receptor andrógeno de câncer, como mcrpc e tnbc, incluindo pacientes diagnosticados com a forma de splice ar-v7.compositions and methods for treating androgen receptor positive forms of cancer. The present invention relates to pharmaceutical compositions comprising a cbp inhibitor compound that can be used to treat patients diagnosed with androgen receptor positive forms of cancer such as mcrpc and tnbc, including patients diagnosed with the ar-v7 splice form.

BR112021018266A 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer BR112021018266A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962819490P 2019-03-15 2019-03-15
US201962819476P 2019-03-15 2019-03-15
US201962819472P 2019-03-15 2019-03-15
US201962819487P 2019-03-15 2019-03-15
US201962819482P 2019-03-15 2019-03-15
US201962821660P 2019-03-21 2019-03-21
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)
PCT/US2020/022823 WO2020190792A1 (en) 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer

Publications (1)

Publication Number Publication Date
BR112021018266A2 true BR112021018266A2 (en) 2022-02-01

Family

ID=72521203

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018266A BR112021018266A2 (en) 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer

Country Status (7)

Country Link
EP (1) EP3938365A4 (en)
CN (1) CN113784967B (en)
AU (1) AU2020241709A1 (en)
BR (1) BR112021018266A2 (en)
CA (1) CA3132995A1 (en)
MX (1) MX2021011154A (en)
WO (1) WO2020190792A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412710A4 (en) * 2009-03-27 2012-08-08 Kowa Co Fused piperidine compound and pharmaceutical agent comprising same
NZ603789A (en) * 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
BR112016011024B1 (en) * 2013-11-18 2020-09-01 Forma Therapeutics, Inc COMPOUND, PHARMACEUTICAL COMPOSITION AND USES OF THE SAME
EP3224258B1 (en) * 2014-11-27 2019-08-14 Genentech, Inc. 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2019055869A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
CN112513038B (en) * 2018-06-29 2023-01-10 福马疗法公司 Inhibition of CREB-binding protein (CBP)

Also Published As

Publication number Publication date
EP3938365A4 (en) 2023-01-25
EP3938365A1 (en) 2022-01-19
WO2020190792A1 (en) 2020-09-24
CN113784967A (en) 2021-12-10
AU2020241709A1 (en) 2021-09-23
CN113784967B (en) 2024-07-26
MX2021011154A (en) 2021-10-22
CA3132995A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CL2019000819A1 (en) Compounds and compositions to inhibit arginase activity. (divisional application 201801134)
CO2019005287A2 (en) Compounds of 7-phenylethylamino-4h-pyrimido [4,5-d] [1,3] -oxazin-2-one as inhibitors of mutant idh1 and idh2
CO2023015484A2 (en) Compound, compositions and methods for the treatment of disorders
CO2020014009A2 (en) Mcl-1 inhibitors
CL2018003588A1 (en) Use of myostatin inhibitors and combination therapies.
CL2018002291A1 (en) Afucosylated anti-fgfr2iiib antibodies (divisional application 201600221)
CL2017000080A1 (en) Methods to treat cancer with tigit inhibitors and anticancer agents
CL2018000198A1 (en) Compositions of transthyretin (ttr) arni and methods for use for the treatment or prevention of diseases associated with ttr
UY37134A (en) HETEROARILE COMPOUNDS AND COMPOSITIONS THAT CONTAIN USEFUL AS PAD4 INHIBITORS
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CR20150571A (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
UY35991A (en) BENCIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
BR112022008294A2 (en) PRODrug COMPOSITIONS AND TREATMENT METHODS
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
CL2019001092A1 (en) Combination treatments that include the administration of imidazopyrazinones.
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
CL2019002427A1 (en) Inhibition of smarca2 for the treatment of cancer.
CO2022000481A2 (en) enzyme inhibitors
BR112019002458A2 (en) compositions and methods for treating arginine-depleted cancer and immuno-oncologic agents
BR112017013982A2 (en) combination drug
MX2017013360A (en) Methods for treating cancer.
CO2022000270A2 (en) enzyme inhibitors
CL2019002583A1 (en) Dual inhibitors of magl and faah.
CL2021001509A1 (en) Substituted xanthine derivatives
CL2019001618A1 (en) Use of carbamate compounds for prevention, relief or treatment of bipolar disorder.